{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:58:48Z","timestamp":1762253928884,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.arcmed.2021.09.004","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T23:48:49Z","timestamp":1634082529000},"page":"113-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"53","author":[{"given":"Lilian Guadalupe","family":"Cano-Cruz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1754-0500","authenticated-orcid":false,"given":"Ana","family":"Barrera-Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Mateos-Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7301-2163","authenticated-orcid":false,"given":"Enrique","family":"Soto-Perez-de-Celis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5870-0523","authenticated-orcid":false,"given":"Javier","family":"Merayo-Chalico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2021.09.004_bib0001","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0002","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0003","unstructured":"World Health Organization Model List of Essential Medicines sL, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. (Accessed January 2, 2021)."},{"key":"10.1016\/j.arcmed.2021.09.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor Drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0005","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods: GLOBOCAN 2018 sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0006","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"suppl_12","key":"10.1016\/j.arcmed.2021.09.004_bib0007","article-title":"Cancer immunotherapy full speed ahead","volume":"28","author":"Melero","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0008","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3390\/toxins12040241","article-title":"Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy","volume":"12","author":"Carlson","year":"2020","journal-title":"Toxins"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrc1529","article-title":"Timeline: Chemotherapy and the war on cancer","volume":"5","author":"Chabner","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrclinonc.2016.65","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pharmthera.2017.03.008","article-title":"Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines","volume":"178","author":"Lohmueller","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0012","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0013","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0014","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"issue":"Suppl 7","key":"10.1016\/j.arcmed.2021.09.004_bib0015","article-title":"Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors","volume":"58","author":"Weinmann","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0016","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","article-title":"Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies","volume":"106","author":"Lute","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0017","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/art.40897","article-title":"Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Up-Regulation Capacity of Post-Activated Lupus B Cells","volume":"71","author":"Stefanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0018","article-title":"Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression","volume":"13","author":"Guo","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0019","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T-cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0020","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0021","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0022","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways","volume":"17","author":"Liu","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0023","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3389\/fonc.2019.00530","article-title":"Immune-Related Adverse Events: A Case-Based Approach","volume":"9","author":"Connolly","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0024","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0025","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0026","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0028","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0031","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2017-211216","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0032","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0033","article-title":"Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: Understanding the diversity in a case series","author":"Wong","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0034","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune Checkpoint Inhibitor-Associated Myositis: Expanding the Spectrum of Cardiac Complications of the Immunotherapy Revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0035","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0036","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 118","key":"10.1016\/j.arcmed.2021.09.004_bib0037","first-page":"114","article-title":"Sicca\/Sjogren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0038","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0039","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0040","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0042","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0043","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1177\/1078155218822707","article-title":"Evaluation of arthralgias in adult oncology patients receiving immune checkpoint inhibitors","volume":"25","author":"Lee","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"Suppl 7","key":"10.1016\/j.arcmed.2021.09.004_bib0044","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1740774520975120","article-title":"Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"18","author":"Basch","year":"2021","journal-title":"Clin Trials"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0046","unstructured":"Cancer.gov. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. (Accessed January 2, 2021)."},{"key":"10.1016\/j.arcmed.2021.09.004_bib0047","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0048","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40264-019-00864-9","article-title":"Rheumatology Common Toxicity Criteria (RCTC): An Update Reflecting Real-World Use","volume":"42","author":"Stach","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0049","unstructured":"National Comprehensive Cancer Network. Management of Immunotherapy-related toxicities. Version 1.2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. (Accessed January 2, 2021)."},{"key":"10.1016\/j.arcmed.2021.09.004_bib0050","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0051","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2020.02023","article-title":"Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities","volume":"11","author":"Xu","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0052","doi-asserted-by":"crossref","first-page":"11919","DOI":"10.1073\/pnas.1611421113","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0053","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1158\/0008-5472.CAN-16-2324","article-title":"Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire","volume":"77","author":"Oh","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0054","doi-asserted-by":"crossref","first-page":"21539","DOI":"10.18632\/oncotarget.15368","article-title":"Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma","volume":"8","author":"de Coana","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12967-018-1467-x","article-title":"Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0056","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0057","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0058","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamaoncol.2019.0402","article-title":"Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer","volume":"5","author":"Berner","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0059","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0060","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","article-title":"Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab","volume":"19","author":"Masuda","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0061","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0062","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0063","article-title":"Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis","author":"Efuni","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0064","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.arcmed.2021.09.004_bib0065","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2217\/imt-2017-0183","article-title":"Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access","volume":"10","author":"Aguiar","year":"2018","journal-title":"Immunotherapy"}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921001934?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0188440921001934?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:51:19Z","timestamp":1759261879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0188440921001934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0188440921001934"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.09.004","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatological Adverse Events of Cancer Therapy with Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2021.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}